Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Endothelial Microparticles in Uremia: Biomarkers and Potential Therapeutic Targets.

Favretto G, Cunha RSD, Dalboni MA, Oliveira RB, Barreto FC, Massy ZA, Stinghen AEM.

Toxins (Basel). 2019 May 13;11(5). pii: E267. doi: 10.3390/toxins11050267. Review.

2.

Vitamin D levels reverberate in monocytes modulation in hemodialysis patients.

Almeida ACSF, Siqueira MC, Bonan NB, Dambiski A, Bertuzzo G, Moreno-Amaral AN, Barreto FC.

J Cell Physiol. 2019 Feb 25. doi: 10.1002/jcp.28290. [Epub ahead of print]

PMID:
30805930
3.

Bone biopsy in nephrology practice.

Barreto FC, Costa CRVD, Reis LMD, Custódio MR.

J Bras Nefrol. 2018 Oct-Dec;40(4):366-374. doi: 10.1590/2175-8239-JBN-2017-0012. Epub 2018 Nov 29. English, Portuguese.

4.

The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: A post hoc analysis.

Hernandez MJ, Dos Reis LM, Marques ID, Araujo MJ, Truyts CAM, Oliveira IB, Barreto FC, David-Neto E, Custodio MR, Moyses RM, Bellorin-Font E, Jorgetti V.

PLoS One. 2018 May 25;13(5):e0197994. doi: 10.1371/journal.pone.0197994. eCollection 2018.

5.

Macrothrombocytopenia, renal dysfunction and nephrotic syndrome in a young male patient: a case report of MYH9-related disease.

Sevignani G, Pavanelli GM, Milano SS, Ferronato BR, Pachaly MA, Ii Cheong H, Carvalho M, Barreto FC.

J Bras Nefrol. 2018 Apr-Jun;40(2):198-200. doi: 10.1590/2175-8239-JBN-3879. Epub 2018 May 17. English, Portuguese.

6.

Sevelamer reduces endothelial inflammatory response to advanced glycation end products.

Gregório PC, Favretto G, Sassaki GL, Cunha RS, Becker-Finco A, Pecoits-Filho R, Souza WM, Barreto FC, Stinghen AEM.

Clin Kidney J. 2018 Feb;11(1):89-98. doi: 10.1093/ckj/sfx074. Epub 2017 Sep 5.

7.

The impact of type 2 diabetes on bone metabolism.

Sanches CP, Vianna AGD, Barreto FC.

Diabetol Metab Syndr. 2017 Oct 19;9:85. doi: 10.1186/s13098-017-0278-1. eCollection 2017. Review.

8.

Predicting the successfulness of parathyroidectomy: new lessons from an old challenge.

Barreto FC, Bucharles SGE.

J Bras Nefrol. 2017 Apr-Jun;39(2):100-101. doi: 10.5935/0101-2800.20170024. English, Portuguese. No abstract available.

9.

Case report: is low α-Gal enzyme activity sufficient to establish the diagnosis of Fabry disease?

Biagini G, Almeida ACSF, Almeida TVR, Silva CAB, Castro BF, Reche TC, Dabinski AC, Barreto FC.

J Bras Nefrol. 2017 Jul-Sep;39(3):333-336. doi: 10.5935/0101-2800.20170057. English, Portuguese.

10.

Review article: effects of type 2 diabetes therapies on bone metabolism.

Vianna AGD, Sanches CP, Barreto FC.

Diabetol Metab Syndr. 2017 Sep 25;9:75. doi: 10.1186/s13098-017-0274-5. eCollection 2017. Review.

11.

Uremia Retention Molecules and Clinical Outcomes.

Barreto FC, Barreto DV, Canziani MEF.

Contrib Nephrol. 2017;191:18-31. doi: 10.1159/000479253. Epub 2017 Sep 14.

PMID:
28910788
12.

A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.

Veloso VSP, Ataides TL, Canziani MEF, Veloso MP, da Silva NA, Barreto DV, Pereira ERS, de Moura LAR, Barreto FC.

Nephron. 2018;138(2):147-156. doi: 10.1159/000479895. Epub 2017 Sep 12.

PMID:
28892806
13.

Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.

Vianna AGD, de Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Borba VZC, Barreto FC.

Diabetol Metab Syndr. 2017 May 15;9:35. doi: 10.1186/s13098-017-0232-2. eCollection 2017.

14.

Comment on Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies. Toxins 2016, 8, 358.

Barreto FC, Barreto DV, Stinghen AEM, Massy ZA.

Toxins (Basel). 2017 Apr 17;9(4). pii: E142. doi: 10.3390/toxins9040142.

15.

The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up study.

Hernandes FR, Canziani ME, Barreto FC, Santos RO, Moreira VM, Rochitte CE, Carvalho AB.

PLoS One. 2017 Apr 6;12(4):e0174811. doi: 10.1371/journal.pone.0174811. eCollection 2017.

16.

p-Cresyl sulfate affects the oxidative burst, phagocytosis process, and antigen presentation of monocyte-derived macrophages.

Azevedo ML, Bonan NB, Dias G, Brehm F, Steiner TM, Souza WM, Stinghen AE, Barreto FC, Elifio-Esposito S, Pecoits-Filho R, Moreno-Amaral AN.

Toxicol Lett. 2016 Nov 30;263:1-5. doi: 10.1016/j.toxlet.2016.10.006. Epub 2016 Oct 17.

PMID:
27760375
17.

Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.

Silva CA, Barreto FC, Dos Reis MA, Moura Junior JA, Cruz CM.

Nephron. 2016;134(4):221-230. Epub 2016 Aug 31.

PMID:
27576502
18.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC.

Cochrane Database Syst Rev. 2016 Jul 25;7:CD006663. doi: 10.1002/14651858.CD006663.pub4. Review.

19.

Parathyroidectomy in chronic kidney disease patients: is it time for changes?

Barreto FC.

J Bras Nefrol. 2016 Jun;38(2):145-6. doi: 10.5935/0101-2800.20160022. English, Portuguese. No abstract available.

20.

The pitfall of treating low bone turnover: Effects on cortical porosity.

Araujo MJ, Karohl C, Elias RM, Barreto FC, Barreto DV, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM.

Bone. 2016 Oct;91:75-80. doi: 10.1016/j.bone.2016.07.009. Epub 2016 Jul 15.

PMID:
27424935
21.

Uremic Toxicity-Induced Eryptosis and Monocyte Modulation: The Erythrophagocytosis as a Novel Pathway to Renal Anemia.

Bonan NB, Steiner TM, Kuntsevich V, Virzì GM, Azevedo M, Nakao LS, Barreto FC, Ronco C, Thijssen S, Kotanko P, Pecoits-Filho R, Moreno-Amaral AN.

Blood Purif. 2016;41(4):317-23. doi: 10.1159/000443784. Epub 2016 Feb 6.

PMID:
26848873
22.

New insights on diabetes and bone metabolism.

Moreira CA, Barreto FC, Dempster DW.

J Bras Nefrol. 2015 Oct-Dec;37(4):490-5. doi: 10.5935/0101-2800.20150077. Review. English, Portuguese.

23.

Peritoneal delivery of sodium pyrophosphate blocks the progression of pre-existing vascular calcification in uremic apolipoprotein-E knockout mice.

de Oliveira RB, Louvet L, Riser BL, Barreto FC, Benchitrit J, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Massy ZA.

Calcif Tissue Int. 2015 Aug;97(2):179-92. doi: 10.1007/s00223-015-0020-7. Epub 2015 Jun 19.

PMID:
26087714
24.

Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease.

de Oliveira RA, Barreto FC, Mendes M, dos Reis LM, Castro JH, Britto ZM, Marques ID, Carvalho AB, Moysés RM, Jorgetti V.

Kidney Int. 2015 May;87(5):1039-45. doi: 10.1038/ki.2014.372. Epub 2014 Dec 10.

PMID:
25493951
25.

Brazilian Registry of Bone Biopsy (REBRABO): design, data elements and methodology.

de Oliveira RB, Barreto FC, Custódio MR, Gueiros JE, Neves CL, Karohl C, Sampaio Ede A, da Costa RM, Canziani ME, Moysés RM, de Carvalho AB, Jorgetti V.

J Bras Nefrol. 2014 Jul-Sep;36(3):352-9. English, Portuguese.

26.

Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients.

Barreto FC, Barreto DV, Canziani ME, Tomiyama C, Higa A, Mozar A, Glorieux G, Vanholder R, Massy Z, de Carvalho AB.

J Bras Nefrol. 2014 Jul-Sep;36(3):289-96. English, Portuguese.

27.

The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins.

Barreto FC, Stinghen AE, de Oliveira RB, Franco AT, Moreno AN, Barreto DV, Pecoits-Filho R, Drüeke TB, Massy ZA.

J Bras Nefrol. 2014 Apr-Jun;36(2):221-35. Review. English, Portuguese.

28.

Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease.

Barreto FC, de Oliveira RB, Benchitrit J, Louvet L, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Riser BL, Massy ZA.

J Bone Miner Metab. 2014 Nov;32(6):636-44. doi: 10.1007/s00774-013-0541-y. Epub 2014 Jan 21.

PMID:
24442863
29.

[Clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease].

Custódio MR, Canziani ME, Moysés RM, Barreto FC, Neves CL, de Oliveira RB, Karohl C, Sampaio Ede A, Gueiros JE, Jorgetti V, de Carvalho AB.

J Bras Nefrol. 2013 Oct-Dec;35(4):308-22. doi: 10.5935/0101-2800.20130050. Portuguese. No abstract available.

30.

Comparison of the activity measurements in nuclear medicine services in the Brazilian northeast region.

de Farias Fragoso Mda C, de Albuquerque AM, de Oliveira ML, de Lima FF, Barreto FC, de Andrade Lima R.

Appl Radiat Isot. 2013 Dec;82:36-44. doi: 10.1016/j.apradiso.2013.07.014. Epub 2013 Jul 24.

PMID:
23948309
31.

Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure.

Maizel J, Six I, Dupont S, Secq E, Dehedin B, Barreto FC, Benchitrit J, Poirot S, Slama M, Tribouilloy C, Choukroun G, Mazière JC, Drueke TB, Massy ZA.

Kidney Int. 2013 Sep;84(3):491-500. doi: 10.1038/ki.2013.110. Epub 2013 Apr 17.

32.

Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease.

Neirynck N, Eloot S, Glorieux G, Barreto DV, Barreto FC, Liabeuf S, Lenglet A, Lemke HD, Massy ZA, Vanholder R.

PLoS One. 2012;7(8):e44201. doi: 10.1371/journal.pone.0044201. Epub 2012 Aug 31.

33.

Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.

Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, Slama M, Tribouilloy C, Choukroun G, Mazière JC, Bode-Boeger S, Kielstein JT, Drüeke TB, Massy ZA.

Cardiovasc Res. 2012 Oct 1;96(1):130-9. doi: 10.1093/cvr/cvs240. Epub 2012 Jul 20.

PMID:
22822101
34.

Pharmacotherapy of chronic kidney disease and mineral bone disorder.

Barreto FC, de Oliveira RA, Oliveira RB, Jorgetti V.

Expert Opin Pharmacother. 2011 Dec;12(17):2627-40. doi: 10.1517/14656566.2011.626768. Epub 2011 Oct 22. Review.

PMID:
22017388
35.

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloot S, Barreto FC, Massy Z, Vanholder R; European Uremic Toxin Work Group (EUTox).

Clin J Am Soc Nephrol. 2011 Oct;6(10):2374-83. doi: 10.2215/CJN.01720211. Epub 2011 Aug 4. Erratum in: Clin J Am Soc Nephrol. 2012 May;7(5):874.

36.

[Aluminium intoxication in chronic kidney disease].

Barreto FC, Araújo SM; Sociedade Brasileira de Nefrologia.

J Bras Nefrol. 2011 Apr-Jun;33(2):211-5. Portuguese. No abstract available.

37.

[Bone biopsy in chronic kidney disease].

Barreto FC, Lucca LJ; Sociedade Brasileira de Nefrologia.

J Bras Nefrol. 2011 Apr-Jun;33(2):225-6. Portuguese. No abstract available.

38.

Inhibitors of vascular calcification as potential therapeutic targets.

Rezg R, Barreto FC, Barreto DV, Liabeuf S, Drüeke TB, Massy ZA.

J Nephrol. 2011 Jul-Aug;24(4):416-27. doi: 10.5301/JN.2011.8420. Review.

PMID:
21688249
39.

[Bone biopsy in chronic kidney disease].

Barreto FC, Lucca LJ; Sociedade Brasileira de Nefrologia.

J Bras Nefrol. 2011 Apr;33 Suppl 1:35-6. Portuguese. No abstract available.

40.

[Aluminium intoxication in chronic kidney disease].

Barreto FC, Araújo SM; Sociedade Brasileira de Nefrologia.

J Bras Nefrol. 2011 Apr;33 Suppl 1:21-5. Portuguese. No abstract available.

41.

Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins.

Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, Verbeke F, Glorieux G, Choukroun G, Massy Z, Vanholder R.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1266-73. doi: 10.2215/CJN.09981110. Epub 2011 May 26.

42.

Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia.

Riser BL, Barreto FC, Rezg R, Valaitis PW, Cook CS, White JA, Gass JH, Maizel J, Louvet L, Drueke TB, Holmes CJ, Massy ZA.

Nephrol Dial Transplant. 2011 Oct;26(10):3349-57. doi: 10.1093/ndt/gfr039. Epub 2011 Mar 11.

PMID:
21398365
43.

High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients.

Liabeuf S, Barreto DV, Kretschmer A, Barreto FC, Renard C, Andrejak M, Choukroun G, Massy Z.

Atherosclerosis. 2011 Mar;215(1):116-24. doi: 10.1016/j.atherosclerosis.2010.11.038. Epub 2010 Dec 5.

PMID:
21183183
44.

KDIGO CKD-MBD Discussion forum: the Brazilian perspective.

Moysés RM, Cancela AL, Gueiros JE, Barreto FC, Neves CL, Canziani ME, Oliveira RB, Jorgetti V, Carvalho AB.

J Bras Nefrol. 2010 Jul-Sep;32(3):229-36.

45.

Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease.

Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A, Slama M, Choukroun G, Brazier M, Massy Z.

Nephron Clin Pract. 2011;117(4):c363-72. doi: 10.1159/000321520. Epub 2010 Nov 12.

PMID:
21071960
46.

Brazilian science towards a phase transition.

Jorio A, Barreto FC, de Sampaio JF, Chacham H.

Nat Mater. 2010 Jul;9(7):528-31. doi: 10.1038/nmat2790. No abstract available.

PMID:
20571476
47.

Vascular calcification is not an independent predictor of mortality in pre-dialysis adult patients.

Barreto FC, Barreto DV, Liabeuf S, Massy ZA.

Nephrol Dial Transplant. 2010 Aug;25(8):2804-5; author reply 2805. doi: 10.1093/ndt/gfq289. Epub 2010 May 26. No abstract available.

PMID:
20507851
48.

Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors.

Massy ZA, Barreto DV, Barreto FC, Vanholder R.

Atherosclerosis. 2010 Aug;211(2):381-3. doi: 10.1016/j.atherosclerosis.2010.04.010. Epub 2010 May 14. No abstract available.

PMID:
20471651
49.

The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.

Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G, Kamel S, Massy ZA.

Nephrol Dial Transplant. 2010 Aug;25(8):2596-602. doi: 10.1093/ndt/gfq042. Epub 2010 Feb 26.

PMID:
20190248
50.

The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report.

Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA.

Clin J Am Soc Nephrol. 2010 Apr;5(4):568-75. doi: 10.2215/CJN.07081009. Epub 2010 Feb 4.

Supplemental Content

Loading ...
Support Center